Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVL, ACLX, ARGX, IRON, CRNX, and represent 38.43% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: SRPT (+$140M), RVMD (+$94M), PCVX (+$85M), ARVN (+$70M), TARS (+$67M), ARGX (+$51M), EWTX (+$45M), KURA (+$40M), CRNX (+$38M), YMAB (+$36M).
- Started 10 new stock positions in CGEM, SRPT, EWTX, APGE, RVMD, YMAB, Kyverna Therapeutics, AGIO, IMVT, PCVX.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$91M), Ambrx Biopharma (-$64M), ALPN (-$42M), AUTL (-$40M), TGTX (-$37M), ZLAB (-$30M), BCYC (-$12M), CRGX, CRBU, AVTE.
- Sold out of its positions in AVTE, Mirati Therapeutics, Ambrx Biopharma, TGTX, ZLAB.
- Paradigm Biocapital Advisors was a net buyer of stock by $544M.
- Paradigm Biocapital Advisors has $2.8B in assets under management (AUM), dropping by 33.00%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 34 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 11.0 | $314M | +8% | 4.2M | 75.09 |
|
| Arcellx Common Stock (ACLX) | 9.3 | $266M | +4% | 3.8M | 69.55 |
|
| Argenx Se Sponsored Adr (ARGX) | 7.7 | $217M | +30% | 552k | 393.72 |
|
| Disc Medicine (IRON) | 5.2 | $149M | 2.4M | 62.26 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 5.1 | $146M | +35% | 3.1M | 46.81 |
|
| Sarepta Therapeutics (SRPT) | 4.9 | $140M | NEW | 1.1M | 129.46 |
|
| Immunocore Hldgs Ads (IMCR) | 4.1 | $116M | +22% | 1.8M | 65.00 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 3.9 | $111M | +4% | 2.0M | 56.09 |
|
| Arvinas Ord (ARVN) | 3.8 | $108M | +180% | 2.6M | 41.28 |
|
| Xenon Pharmaceuticals (XENE) | 3.8 | $107M | +16% | 2.5M | 43.05 |
|
| Tarsus Pharmaceuticals (TARS) | 3.7 | $104M | +179% | 2.9M | 36.35 |
|
| Cerevel Therapeutics Hldng I (CERE) | 3.5 | $99M | 2.3M | 42.27 |
|
|
| Revolution Medicines (RVMD) | 3.3 | $94M | NEW | 2.9M | 32.23 |
|
| Olema Pharmaceuticals (OLMA) | 3.1 | $90M | 7.9M | 11.32 |
|
|
| Miragen Therapeutics (VRDN) | 3.1 | $88M | +4% | 5.0M | 17.51 |
|
| Vaxcyte (PCVX) | 3.0 | $85M | NEW | 1.2M | 68.31 |
|
| Alpine Immune Sciences (ALPN) | 3.0 | $84M | -33% | 2.1M | 39.64 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 2.8 | $81M | -12% | 3.2M | 24.90 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.7 | $77M | +44% | 508k | 151.17 |
|
| Kura Oncology (KURA) | 2.4 | $67M | +148% | 3.1M | 21.33 |
|
| Edgewise Therapeutics (EWTX) | 1.6 | $45M | NEW | 2.4M | 18.24 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.4 | $41M | -49% | 6.4M | 6.38 |
|
| Y Mabs Therapeutics (YMAB) | 1.3 | $36M | NEW | 2.2M | 16.26 |
|
| Immatics SHS (IMTX) | 1.0 | $30M | +31% | 2.8M | 10.51 |
|
| Immunovant (IMVT) | 0.9 | $26M | NEW | 799k | 32.31 |
|
| Cullinan Oncology (CGEM) | 0.8 | $23M | NEW | 1.3M | 17.04 |
|
| Apogee Therapeutics (APGE) | 0.8 | $22M | NEW | 330k | 66.45 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.7 | $20M | +5% | 2.4M | 8.32 |
|
| Vor Biopharma (VOR) | 0.5 | $15M | 6.5M | 2.37 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.5 | $15M | +136% | 945k | 15.76 |
|
| Agios Pharmaceuticals (AGIO) | 0.4 | $12M | NEW | 400k | 29.24 |
|
| Caribou Biosciences (CRBU) | 0.4 | $11M | -25% | 2.2M | 5.14 |
|
| Cargo Therapeutics (CRGX) | 0.1 | $3.3M | -55% | 148k | 22.32 |
|
| Kyverna Therapeutics | 0.0 | $1.2M | NEW | 50k | 24.84 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2024 Q1 filed May 15, 2024
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022
- Paradigm Biocapital Advisors 2022 Q2 filed Aug. 15, 2022
- Paradigm Biocapital Advisors 2022 Q1 filed May 16, 2022
- Paradigm Biocapital Advisors 2021 Q4 filed Feb. 14, 2022